Compare BioNano Genomics Inc (BNGO) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Nu Holdings Ltd — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Nu Holdings Ltd trades at $13.73 (market cap $65.94B). The key difference: Nu Holdings Ltd is far larger — about 4827.2× BioNano Genomics Inc's market cap, and Nu Holdings Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | NU | |
|---|---|---|
Market Cap | $13.66M | $65.94B |
Sector | Health | Financials |
52-Week High | $4.92 | $18.76 |
52-Week Low | $1.06 | $11.60 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
NU stock trades at $13.86, up 0.14% today, with a bullish technical signal despite recent earnings misses. Revenue grew from $3.0B in 2022 to $10.6B in 2025, with net income turning positive to $2.9B. The company's expansion in Brazil and Mexico, including a pending banking license acquisition (PYMNTS, 2026-07-22), supports growth. Analysts maintain a buy consensus with a $14.98 target, though competition and Latin American market risks persist.
Outlook remains positive due to strong fundamentals and growth trajectory, but investors face risks from rising competition and regional volatility. The upcoming Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) serves as a key catalyst, with expectations of $0.1984 EPS. Institutional activity is mixed, with some trimming stakes while others increase holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
